Mabion SA
Research Mabion SA (MAB.WA) on Bullrun: market cap PLN 126.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMAB.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 126.87M
- Financial periodQ1 2026
- RevenuePLN 4.57M
- Net income-PLN 9.74M
- Free cash flow-PLN 12.10M
- Gross margin-62.3%
Valuation Snapshot
latest market cap is PLN 126.87M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | PLN 126.87M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About Mabion SA
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mabion SA's market cap?
Mabion SA's market capitalization is PLN 126.87M.
What does Mabion SA do?
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.